Directorate Change

RNS Number : 7426P

Tissue Regenix Group PLC

22 November 2016

 

Tissue Regenix Group plc

Directorate Change

Leeds, 22 November 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Company") the regenerative medical devices company announces Chief Financial Officer, Ian Jefferson, has notified the Board of his intention to leave the Company. He will remain available to support the Company whilst the search for a successor is completed, and throughout the transition period. 

Antony Odell, CEO, Tissue Regenix Group plc: "We would like to thank Ian for his commitment to Tissue Regenix over the last 5 years, and we wish him all the best in the future"

For more Information:

Tissue Regenix Group plc Caitlin Pearson                                 Corporate Communications Officer	Tel: [phone]
Jefferies International Ltd Simon Hardy / Harry Nicholas	Tel:  [phone]

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

 In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

END

 

 

BOAPGGBCGUPQGAG